Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients

Palumbo, Barbara; Parnetti, Lucilla; Nocentini, Giuseppe; Cardinali, Laura; Brancorsini, Stefano; Riccardi, Carlo; Senin, Umberto

doi:10.1016/s0304-3940(97)00538-7

Cited by 26 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results vary from increased frequencies, similar to those found for AD [38,39], to no association at all [40,41]. In a previous study, we found that there was no association between ApoE Â4 and vascular dementia or cognitive impairment due to clinical cerebrovascular disease, but that ApoE Â4 was much more frequent in AD and mixed dementia [42].…”

Section: Discussionsupporting

confidence: 53%

Association of the Apolipoprotein E ε4 Allele with Late-Onset Depression

et al. 2001

View full text Add to dashboard Cite

Apolipoprotein E (ApoE) phenotyping was determined in 42 subjects with Alzheimer’s disease (AD), 49 with depression, including 26 with early-onset depression (EOD) and 23 with late-onset depression (LOD), and 49 controls. In the EOD group, the frequency of the ApoE Ε4 allele was not different from the control frequency (p = 0.532) but was significantly lower than in AD (p < 0.001). In the LOD group, the ApoE Ε4 frequency was significantly higher than in the controls (p = 0.034) but was not different from that in the AD group (p = 0.229). Individuals with ApoE Ε4 were at greater risk of getting AD (odds ratio, OR = 5.5, 95% confidence interval, CI, 2.0–14.0) or LOD (OR = 6.1, 95% CI, 1.9–19.0) than of EOD (OR = 0.7, 95% CI, 0.2–2.5). These results suggest an association between the ApoE Ε4 allele frequency and LOD. Patients with LOD could be at risk of developing AD by an Ε4-dependent pathway.

show abstract

Section: Discussionsupporting

confidence: 53%

Association of the Apolipoprotein E ε4 Allele with Late-Onset Depression

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Previous reports on an association between ApoE ε4 and VaD have been mixed. [11][12][13][14][15][16][17][18][19] These inconsistencies may be a result of population stratificationsubjects who differ in their ethnic background may possess different genetic susceptibility loci. Also, results of some of the smaller studies may be negative because of inadequate power.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 The ApoE ε4 allele also has been implicated as a risk factor for vascular dementia (VaD), but the findings have been inconsistent, with some studies showing positive association [10][11][12][13][14] and others not. [15][16][17][18][19] Recently, it has been recognized that patients who have "cognitive impairment but no dementia" (CIND) are an important group at risk for dementia. Few studies have examined ApoE ε4 as a predictor for progression from normal to CIND and from CIND to dementia.…”

mentioning

confidence: 99%

“…Few studies have examined ApoE ε4 as a predictor for progression from normal to CIND and from CIND to dementia. 17,19,20 To further define the relation between ApoE ε4 polymorphism and the risk of dementia in the Canadian population, we examined ApoE ε4 genotype as a predictor for conversion from normal to CIND and from CIND to AD or VaD using data obtained from the CSHA cohort. We also investigated the role of ApoE ε4 genotype as a risk factor for incident cases of AD and VaD, while controlling for the effects of age, sex and level of education.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Apolipoprotein E 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

Hsiung

Sadovnick²,

Feldman³

2004

Canadian Medical Association Journal

148

View full text Add to dashboard Cite

Background: Apolipoprotein E (ApoE) ε4 genotype is a wellestablished risk factor for Alzheimer's disease (AD). However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear. Methods:We used a nested case-control design from the population-based Canadian Study of Health and Aging (CSHA) to examine the effect of ApoE ε4 genotype on the conversion of subjects from normal to CIND and from CIND to AD. We also contrasted these findings with incident cases of AD and vascular dementia (VaD) in the CSHA cohort. Results: The ApoE ε4 genotype was a significant risk factor for conversion from CIND to AD and from normal to AD and VaD. However, it was not a significant risk factor for conversion from normal to CIND. This effect is robust to adjustment for age, sex and education level. There is significant interaction between the ApoE ε4 genotype and age for AD and for conversion from CIND to AD. No interaction between ApoE ε4 genotype, sex, age, ethnicity and education level was found in other subgroup analyses. The positive predictive value of ApoE ε4 for predicting CIND conversion to AD was 0.48, and the negative predictive value was 0.65. Interpretation: Possession of an ApoE ε4 allele increases the risk of AD developing from CIND. It is also associated with a decrease in the age at onset of AD. Its predictive values do not support its utility as a diagnostic test for predicting progression from CIND to AD, but it may be useful in research studies to enrich study samples that have a higher rate of progression to AD.

show abstract

“…As yet there is no clear pattern of particular neuroimaging or genetic associations (Palumbo et al, 1997), although, as previously indicated, hippocampal changes may be important. A number of treatment studies have been reported, with mixed results (Riedel & Jolles, 1996).…”

Section: Age-associated Memory Impairmentmentioning

confidence: 85%

Age-associated memory impairment and related disorders

O’Brien¹

1999

Adv. psychiatr. treat

View full text Add to dashboard Cite

Complaints of poor memory are common in the healthy elderly and to many it may seem unsurprising that cognitive function declines with ‘normal’ ageing. Virtually every biological system alters with age and, just as a 70-year-old cannot run as fast or hear as well as when he or she was 20, it is perhaps inevitable that cognitive function also becomes impaired. However, far from being straightforward, the nature, classification and clinical significance of age-related cognitive changes that fall short of dementia remain a most controversial and difficult area (see O'Brien & Beats, 1994; Dal Forno & Kawas, 1995). The recent emergence of new drugs for the treatment of Alzheimer's disease (donepezil and rivastigmine) and related disorders has emphasised the need to study groups with milder degrees of cognitive impairment. It is necessary to determine whether such conditions are benign and non-progressive, or harbingers of progressive dementia and so appropriate conditions to target for early therapeutic intervention. The presence of age-related cognitive changes raises other important issues including why such changes occur, how they should be classified and whether, even if ‘benign’, they can and should be treated.

show abstract

Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients

Cited by 26 publications

References 15 publications

Association of the Apolipoprotein E ε4 Allele with Late-Onset Depression

Association of the Apolipoprotein E ε4 Allele with Late-Onset Depression

Apolipoprotein E 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

Age-associated memory impairment and related disorders

Contact Info

Product

Resources

About